Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)

v3.19.3
Basis of Presentation and Significant Accounting Policies (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Oct. 31, 2018
Noncontrolling Interest [Line Items]            
Accumulated deficit $ 101,261,124   $ 101,261,124   $ 84,580,180  
Net loss non-controlling interest (136,315) $ (265,024) (413,955) $ (668,219)    
Operating lease right-of-use assets 520,399   520,399      
Operating lease liabilities $ 528,253   $ 528,253      
Pelican Therapeutics, Inc. [Member]            
Noncontrolling Interest [Line Items]            
Percentage of voting interests acquired in acquisition 85.00% 80.00% 85.00% 80.00%   85.00%
Heat I [Member]            
Noncontrolling Interest [Line Items]            
Percentage of voting interests acquired in acquisition   92.50%   92.50% 100.00%  
Net loss non-controlling interest       $ 223,487    
Pelican [Member]            
Noncontrolling Interest [Line Items]            
Net loss non-controlling interest       $ 444,732